Patent classifications
C07D405/14
GLP-1 RECEPTOR AGONIST
The present invention relates to a compound represented by Formula 1 wherein A, B, L, X, and R.sub.1 to R.sub.6 are as described herein, or a pharmaceutically acceptable salt thereof, which serves as a GLP-1 receptor agonist and may be useful in the prevention or treatment of a disease associated with GLP-1 activity.
GLP-1 RECEPTOR AGONIST
The present invention relates to a compound represented by Formula 1 wherein A, B, L, X, and R.sub.1 to R.sub.6 are as described herein, or a pharmaceutically acceptable salt thereof, which serves as a GLP-1 receptor agonist and may be useful in the prevention or treatment of a disease associated with GLP-1 activity.
BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR
Disclosed is a biarylamide compound as a Pan-RAF kinase inhibitor, and specifically disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.
##STR00001##
BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR
Disclosed is a biarylamide compound as a Pan-RAF kinase inhibitor, and specifically disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.
##STR00001##
INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS
Provided herein are indole compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease
INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS
Provided herein are indole compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease
Bicyclic Compounds and their Uses
- Vincent Bordas ,
- Jvan BRUN ,
- Andrea DECKER ,
- Markus Furegati ,
- Geoffrey GOGNIAT ,
- Wanben GONG ,
- Jacques HAMON ,
- Jürgen Hans-Hermann HINRICHS ,
- Philipp Holzer ,
- Fatma LIMAM ,
- Henrik MÖBITZ ,
- Sandro NOCITO ,
- Simone PLATTNER ,
- Niko Schmiedeberg ,
- Joseph Schoepfer ,
- Jessica SOTO ,
- Ross Sinclair STRANG ,
- Shuping YAO ,
- Huangchao YU ,
- Frédéric ZECRI ,
- Sisi ZHANG
The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I):
##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.26, R.sub.27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.
Bicyclic Compounds and their Uses
- Vincent Bordas ,
- Jvan BRUN ,
- Andrea DECKER ,
- Markus Furegati ,
- Geoffrey GOGNIAT ,
- Wanben GONG ,
- Jacques HAMON ,
- Jürgen Hans-Hermann HINRICHS ,
- Philipp Holzer ,
- Fatma LIMAM ,
- Henrik MÖBITZ ,
- Sandro NOCITO ,
- Simone PLATTNER ,
- Niko Schmiedeberg ,
- Joseph Schoepfer ,
- Jessica SOTO ,
- Ross Sinclair STRANG ,
- Shuping YAO ,
- Huangchao YU ,
- Frédéric ZECRI ,
- Sisi ZHANG
The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I):
##STR00001##
wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.26, R.sub.27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.
Inhibitors of LRRK2 kinase
Compounds having activity as inhibitors of LRRK2 kinase are provided. The compounds have Structure (I): ##STR00001##
or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R.sup.1a, R.sup.1b, R.sup.2, and L are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of LRRK2 kinase are also provided.
Inhibitors of LRRK2 kinase
Compounds having activity as inhibitors of LRRK2 kinase are provided. The compounds have Structure (I): ##STR00001##
or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R.sup.1a, R.sup.1b, R.sup.2, and L are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of LRRK2 kinase are also provided.